Latin American regulatory reform boosts 20% growth in international trials
This article was originally published in Clinica
Executive Summary
The modernisation of clinical trial regulations in Latin America has contributed to a 20% rise in the number of international studies over the last four years, according to the US FDA's newsletter, Clinical Trials Advisor (October 16). Citing expert opinion, including from Wendy Buckland, vice-president of clinical development for Latin America at contract research organisation PPD, it reports that there are currently 323 trials (medtech and pharma) under way in Brazil, 292 in Mexico and 107 in Colombia.
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.